No Data
Huiyu Pharmaceutical (688553.SH): Re-certified as a high-tech enterprise.
On December 31, Gelonghui reported that Huayu Pharmaceutical (688553.SH) announced that according to the announcement released on December 30, 2024, by the Office of the National High-tech Enterprises Recognition Management Work Leading Group, the company has been included in the third batch of high-tech enterprises recognized and filed by the Sichuan Province Recognition Institutions in 2024. The company has once again passed the recognition of high-tech enterprises, with certificate number: GR202451002753, valid for three years. The company previously passed the recognition of high-tech enterprises in 2021.
Huiyu Pharmaceutical (688553.SH): The first subject has been administered in the phase I clinical trial of HY-2003.
On December 27, Gelonghui reported that Huiyu Pharmaceutical (688553.SH) announced that its self-developed HY-2003 is currently conducting Phase I clinical trials for the treatment of excessive submental fat accumulation in individuals, having recently successfully completed the first dose administration for a subject. HY-2003 is a Class 2.2 improved new Chemical Drug, intended to improve moderate to severe contour protrusion caused by submental fat accumulation in adults.
US FDA Approves Huiyu Pharma's Abbreviated New Drug Application for Anti-Cancer Injection
Does Sichuan Huiyu Pharmaceutical (SHSE:688553) Have A Healthy Balance Sheet?
Huiyu Pharmaceutical's Four Drugs Enter European, Egyptian Markets
Huiyu Pharmaceutical (688553.SH) has obtained marketing approval for its Pharmaceuticals in Egypt, Spain, Portugal, and Germany.
Huayu Pharmaceutical (688553.SH) announced that its wholly-owned subsidiary Seacross Phar...
Sichuan Huiyu Pharmaceutical Co., Ltd.'s (SHSE:688553) Stock Is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?
